ScreenerHero

AVLN Avalyn Pharma Inc.

NAS · US · Healthcare · Biotechnology · avalynpharma.com
25.53USD+0.39%Mkt Cap: 1.13B $P/E: —

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company pr…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD
HeadlineSourceTime
Older
Avalyn Pharma (AVLN) Following AP02 Phase 1 Data Is Its Valuation Too Pricey

Avalyn Pharma (AVLN) is back on investor screens after Respiratory Research published full Phase 1 data for AP02, its inhaled nintedanib program for idiopathic pulmonary fibrosis, validating Avalyn’s direct-to-lung delivery approach. Avalyn Pharma’s share price sits at US$32.45 after a 1-day share price return of 2.62%, which partly offsets a 30-day share price return that declined 15.43%. However, the 90-day and year-to-date share price returns of 7.84% and 10.04% suggest momentum has been...

Simply Wall St.
What It Means To Hold Moderna Stock In A Crash

The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.

Trefis